Prothena (PRTA) to Release Quarterly Earnings on Monday

Prothena (NASDAQ:PRTA – Get Rating) is scheduled to release its earnings data after the market closes on Monday, August 8th. Analysts expect Prothena to post earnings of ($0.50) per share for the quarter.

Prothena (NASDAQ:PRTA – Get Rating) last issued its earnings results on Thursday, May 5th. The biotechnology company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.07. Prothena had a return on equity of 16.02% and a net margin of 33.45%. The company had revenue of $1.15 million for the quarter, compared to analysts’ expectations of $0.23 million. On average, analysts expect Prothena to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Prothena Stock Up 2.6 %

Shares of PRTA opened at $33.11 on Friday. Prothena has a 12-month low of $21.06 and a 12-month high of $79.75. The business’s fifty day moving average is $28.49 and its 200 day moving average is $31.58. The stock has a market cap of $1.55 billion, a P/E ratio of 27.14 and a beta of 1.31.

Insider Transactions at Prothena

In other news, CEO Gene G. Kinney sold 21,506 shares of Prothena stock in a transaction on Friday, August 5th. The stock was sold at an average price of $32.83, for a total transaction of $706,041.98. Following the sale, the chief executive officer now directly owns 12,793 shares in the company, valued at approximately $419,994.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Hideki Garren sold 4,000 shares of Prothena stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $30.52, for a total value of $122,080.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Gene G. Kinney sold 21,506 shares of Prothena stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $32.83, for a total value of $706,041.98. Following the completion of the sale, the chief executive officer now directly owns 12,793 shares of the company’s stock, valued at approximately $419,994.19. The disclosure for this sale can be found here. Insiders have sold 98,322 shares of company stock worth $3,180,399 in the last ninety days. Company insiders own 31.20% of the company’s stock.

Institutional Investors Weigh In On Prothena

Several large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its holdings in Prothena by 1.2% during the 1st quarter. Bank of New York Mellon Corp now owns 154,281 shares of the biotechnology company’s stock valued at $5,642,000 after buying an additional 1,821 shares in the last quarter. HighTower Advisors LLC purchased a new position in Prothena during the 1st quarter valued at about $286,000. Dimensional Fund Advisors LP grew its holdings in shares of Prothena by 0.4% during the first quarter. Dimensional Fund Advisors LP now owns 1,505,156 shares of the biotechnology company’s stock worth $55,044,000 after purchasing an additional 6,619 shares in the last quarter. First Light Asset Management LLC grew its holdings in shares of Prothena by 13.3% during the first quarter. First Light Asset Management LLC now owns 1,838,548 shares of the biotechnology company’s stock worth $67,236,000 after purchasing an additional 215,607 shares in the last quarter. Finally, Mariner LLC grew its holdings in shares of Prothena by 430.0% during the first quarter. Mariner LLC now owns 74,130 shares of the biotechnology company’s stock worth $2,711,000 after purchasing an additional 60,144 shares in the last quarter. Hedge funds and other institutional investors own 92.64% of the company’s stock.

Wall Street Analyst Weigh In

Separately, JMP Securities dropped their price objective on Prothena from $77.00 to $50.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 25th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $70.33.

About Prothena

(Get Rating)

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.